Incyte Corp. (INCY)
126.75
-1.25
(-0.98%)
USD |
NASDAQ |
Sep 04, 16:00
128.05
+1.30
(+1.03%)
After-Hours: 20:00
Incyte SG&A Expense (TTM) : 1.399B for June 30, 2026
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.399B |
| March 31, 2026 | 1.379B |
| December 31, 2025 | 1.376B |
| September 30, 2025 | 1.313B |
| June 30, 2025 | 1.293B |
| March 31, 2025 | 1.268B |
| December 31, 2024 | 1.242B |
| September 30, 2024 | 1.209B |
| June 30, 2024 | 1.168B |
| March 31, 2024 | 1.146B |
| December 31, 2023 | 1.161B |
| September 30, 2023 | 1.140B |
| June 30, 2023 | 1.139B |
| March 31, 2023 | 1.108B |
| December 31, 2022 | 1.002B |
| September 30, 2022 | 955.52M |
| June 30, 2022 | 879.77M |
| March 31, 2022 | 795.35M |
| December 31, 2021 | 739.56M |
| September 30, 2021 | 680.35M |
| June 30, 2021 | 610.43M |
| March 31, 2021 | 559.57M |
| December 31, 2020 | 516.92M |
| September 30, 2020 | 486.11M |
| June 30, 2020 | 467.93M |
| Date | Value |
|---|---|
| March 31, 2020 | 455.88M |
| December 31, 2019 | 468.71M |
| September 30, 2019 | 440.89M |
| June 30, 2019 | 434.81M |
| March 31, 2019 | 436.89M |
| December 31, 2018 | 434.41M |
| September 30, 2018 | 423.88M |
| June 30, 2018 | 418.62M |
| March 31, 2018 | 400.66M |
| December 31, 2017 | 366.39M |
| September 30, 2017 | 364.65M |
| June 30, 2017 | 349.16M |
| March 31, 2017 | 325.89M |
| December 31, 2016 | 303.25M |
| September 30, 2016 | 259.63M |
| June 30, 2016 | 231.45M |
| March 31, 2016 | 216.34M |
| December 31, 2015 | 196.62M |
| September 30, 2015 | 192.60M |
| June 30, 2015 | 184.45M |
| March 31, 2015 | 173.67M |
| December 31, 2014 | 165.77M |
| September 30, 2014 | 155.35M |
| June 30, 2014 | 142.35M |
| March 31, 2014 | 124.70M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Mirum Pharmaceuticals, Inc. | 313.84M |
| Regeneron Pharmaceuticals, Inc. | 2.743B |
| Eli Lilly & Co. | 12.24B |
| AbbVie, Inc. | 14.67B |
| Biogen, Inc. | 2.594B |